Abstract
Treatment of mucosal bleeding (epistaxis, gastrointestinal and menorrhagia) and joint bleeding remains problematic in clinically severe von Willebrand Disease (VWD). Patients are often unresponsive to treatment (e.g. desmopressin or antifibrinolytic therapy) and may require von Willebrand (VW) factor replacement therapy. There are little data on the use of prophylaxis in VWD and none applied in a prospective, treatment escalation design.
Original language | English |
---|---|
Pages (from-to) | 1585-1589 |
Journal | Journal of Thrombosis and Haemostasis |
Volume | 13 |
Issue number | 9 |
DOIs | |
Publication status | Published - 2015 |
Subject classification (UKÄ)
- Cardiac and Cardiovascular Systems